Generated by AI
Comera Life Sciences Holdings Inc. is a biotechnology company focused on transforming the way biologic medicines are delivered to patients. Leveraging expertise in formulation science, the company is dedicated to converting essential intravenous (IV) biologic therapies into subcutaneous (SQ) forms. This innovation is designed to make treatments more accessible, allowing patients greater autonomy through self-injectable options and reducing dependency on healthcare institutions. Comera Life Sciences’ proprietary SQore platform underpins this approach, aiming to improve the convenience and quality of care for individuals with chronic conditions. The company's most advanced pipeline candidate, CLS-001, is a subcutaneous version of vedolizumab for the treatment of inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis. Founded in 2014 and based in Woburn, Massachusetts, Comera Life Sciences is part of the healthcare sector and contributes to the evolving landscape of patient-centric biopharmaceuticals by focusing on novel drug delivery solutions.
Website12 Gill Street
Woburn, MA, 01801
United States
Summary of Nov 17's posts. Generated by AI.
Summary of Sep 16's posts. Generated by AI.
Summary of Sep 14's posts. Generated by AI.
Summary of Sep 16's posts. Generated by AI.
Investors talking about CMRA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.